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ABSTRACT 
The aim of the present study was to assess the frequency of stromal myofibroblasts 
appearance, and to further clarify whether myofibroblasts influence tumor suppression or 
progression. Surgical resection specimens from 152 patients with cT1-T3N0 oral squamous 
cell carcinoma (OSCC) were analysed. Frequency of myofibroblasts within tumoral stroma 
was assessed immunohistochemically and compared with other clinically and 
histopathological factors. Immunohistochemical reaction for alpha-smooth muscle actin 
showed positive cells in stroma of 84.2% (n=128) of OSCC. Increased presence of 
myofibroblasts in the tumor stroma was significantly correlated with T stage (P = 0.019), 
presence of occult neck metastases (P < 0.001), regional recurrence (P = 0.037), and distant 
metastases (P = 0.008). There was also association between presence of myofibroblasts and 
patient’s survival (P = 0.009). Presence of myofibroblasts was not associated with local 
recurrence, tumor cellular differentation, mode of invasion, and bone invasion. Results of this 
study suggest that myofibroblast proliferation facilitates tumour invasion, occurrence of 
occult neck disease and distant metastases. Survival rate was poorer in patients with abundant 
myofibroblasts. Further investigations on tumor-associated stroma at invasive front are 
needed in order to provide new diagnostic markers and therapeutic strategies. 
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

INTRODUCTION 
Oral cancer is common worldwide, particularly in developing countries, where it constitutes 
up to 25% of all malignancies
1
. Squamous cell carcinoma is the most common histological 
type of oral cancer. It is associated with great morbidity and mortality rates that have not 
improved in decades despite early detection and therapeutic advances
2
. Extensive research in 
the field of tumorigenesis has shown that tumor progression depends on its genetic 
characteristics and on interactions with its environment
3
. The tumor microenvironment 
comprise cancer cells, stromal cells and extracellular matrix (ECM)
4
. One of the major 
components of tumor-associated stroma are fibroblasts and myofibroblasts. Due to their 
ability to produce collagen and ECM proteins, it has been suggested that these cells represent 
an important factor in the development of the desmoplastic reaction that facilitates invasion 
both in vitro and in vivo
5-7
. Most of the biological markers of metastases are derived from 
cancer cells rather than the stroma. However, assessment of the tumor-host borderline 
provides a correlation with prognosis and understanding the mode of tumour cell invasion 
which enables prediction of the treatment outcome
8-10
.
 
The aim of the present study is to 
assess the abundance of stromal myofibroblasts (SMF), and to correlate it with cancer 
recurrence and patient’s survival. In addition, we investigated the relationship between 
myofibroblast appearance and the incidence of occult neck disease in order to clarify the 
indications for elective lymphadenectomy and the outcome of treatment.  


MATERIALS AND METHODS 
Informed consent was obtained from each patient and the study was carried out with the 
approval of the Ethical Committee of the University of Zagreb School of Medicine, 
University Hospital Dubrava. The study included 152 consecutive patients with cT1-T3N0 
oral squamous cell carcinoma (OSCC) who were diagnosed and surgically treated between 
2000 and 2004 at the Department of Maxillofacial Surgery, University Hospital Dubrava, 
Zagreb, Croatia. Inclusion criteria were: primary surgical treatment, no clinical evidence of 
regional metastases (cN0), no prior treatment for OSCC, no significant comorbidities, and a 
follow up period of at least six months. Standard surgical treatment included intraoral 
excision for cT1 tumors and intraoral excision +/- elective neck dissection for cT2-T3 tumors. 
Bilateral lymphadenectomy was performed only in cases when primary tumors approached 
the midline. Patient monitoring was concluded on the 31
st
 of October 2007. 
 
Staging of the disease was based on the international TNM classification from 2009.
11
 
Patients with adverse histopathological features (positive margin, perineural invasion, 
extracapsular spread, pT3 or pT4 primary) underwent postoperative irradiation. With daily 
fractions of 2 Gy, a prophylactic dose of 50 Gy to uninvolved neck levels was given, followed 
by 60 Gy to the tumor bed with a boost of 66 Gy being applied to sites of increased 
recurrence risk, especially regions of the neck with extracapsular nodal disease and 
microscopically involved margins. Tumor volumes, (mm
3
), were calculated from 
measurements of the tumour diameter and depth of invasion. It was assumed that tumors are 
approximately cones whose volume is r
2πh/3. Margin status was defined as negative when the 
tumor was ≥4mm from the inked surgical margin. Immunohistochemistry was performed by 
sensitive peroxidase-streptavidin method on formalin-fixed, paraffin embedded tissue. Four 
µm-thick sections were cut from 152 blocks containing representative specimen of study 


cases and stained with monoclonal antibody against alpha-smooth muscle actin (α-SMA) 
diluted 1:200 (Dako, Glostrup, Denmark). Proliferation of myofibroblasts within tumour 
stroma was assesed semiquantitatively based on a 4-scale scoring system: 0 = no 
myofibroblasts, 1 = present up to 25% of stroma, 2 = present in 26-50% of stroma, 3 = present 
in 51-75% of stroma, and 4 = present in more than 76% of stroma. For purposes of statistical 
analysis, cases with low scores (0 and 1) were combined and compared to cases with high 
scores (2, 3 and 4). 
The mode of cancer invasion was evaluated according to the classification proposed by 
Yamammoto
8
, and modified by Bryne et al.
12
 where only the most invasive parts of the tumor 
(deep invasive margins) were graded. 
Follow-up protocol consisted of history and physical examination every 3, 6, 9 and 12 
months, in the first, second, third, and fourth year of follow-up, respectively. Post-treatment 
CT scans (oral cavity and neck) were performed within 1 and 5 years after surgical treatment. 
Other repeated imaging was done only in patients with signs/symptoms, not routinely in 
asymptomatic patients. 
 
Statistical Analysis 
Numerical data were presented with mean and standard deviation and categorical with 
absolute and relative frequencies. Follow-up  intervals were  calculated  in  months  from  the  
date of first  treatment  to the  date of  last  follow-up or death. Association between presence 
of myofibroblasts and clinicopathological parameters was performed by Chi-square test or 
Fisher’s exact test when appropriate. Multivariate analysis of variables related to regional 
metastases was done using logistic regression. The Kaplan-Meier method was applied for 
survival analysis, and the statistical significance was evaluated using log-rank test. Regression 
data were presented with regression coefficients and odds ratio with 95% confidence intervals 


(95% CIs). All statistics was done using MedCalc statistical software (MedCalc Statistical 
Software ver. 13.0.2, MedCalc Software bvba, Ostend, Belgium). P values of < 0.05 were 
considered statistically significant. 


RESULTS 
Over the 5-year period, 183 patients were primarily surgically treated. After eliminating 
patients who did not meet inclusion criteria, 152 patients were egliable for study. The study 
group included 124 men (81.6%) and 28 (18.4%) women with a median age of 59 (range 34-
85 years). Clinicopathological characteristics of the study group are summarized in Table 1. 
Immunohistochemical reaction for α-SMA showed positive cells in the stroma of 84.2% (n = 
128) of OSCC. Scanty presence of myofibroblasts was observed in 42 (32.8%) of OSCC 
positive samples, whereas 86 (67.2%) samples demonstrated an abundant distribution of 
myofiboblasts (Figure 1, 2 and 3). The univariate clinicopathological correlations with the 
presence of myofibroblasts are listed in Table 2. Abundant presence of myofibroblasts in the 
tumor stroma significantly correlated with T stage, presence of occult neck metastases, 
regional recurrence, and distant metastases. There was also an association between the 
presence of myofibroblasts and patient’s survival. Patients whose specimens demonstrated 
abundant  myofibroblasts had a disease specific survival rate of 67.2% at 5-years compared 
with 91.9% for patients with scanty myofibroblasts which is statistically significant (Figure 
4). Presence of myofibroblasts was not associated with age, gender, local recurrence, tumor 
cell differentation, mode of invasion, bone invasion, and margin status. We also carried out a 
multivariate analysis, which identified high myofibroblast scores and poorly differantiated 
tumors as unfavorable prognostic factors with respect to occult neck metastases (Table 3). 
The odds of occult neck disease for patients with high myofibroblast scores and poorly 
differentiated tumors were 8.68 and 2.31 higher compared to patients with low myofibroblasts 
scores and moderate/well differantiated tumors, respectively (P < 0.001, 95% CI: 2.87-26.29; 
P = 0.044, 95% CI: 1.02-5.25). Postoperative radiotherapy was administered to 69 of 152 
(45.4%) patients. At the end of the study, thirty-four of the patients had died (22.4%) of 


disease recurrence. Follow-up information was available for all patients and ranged from 7 to 
91 months (mean 43). 


DISCUSSION 
The most significant prognostic factor of survival for patients with OSCC is the status of 
regional lymph nodes. The presence of regional metastases reduces survival of these patients 
up to 50% and indicates the higher risk for regional recurrence and distant metastasis
13,14
. 
However, indications for elective neck dissection in early OSCC are still controversial. The 
aim of the present study was to analyse the relationship between appearance of SMF and the 
incidence of occult neck disease, distant metastases and survival of patients with cT1-T3N0 
OSCC in order to clarify the indications for elective neck dissection. To our knowledge this is 
the largest study in the English literature examining the role of SMF proliferation in 
squamous cell carcinoma of the oral cavity and the first one analysing the role of its 
proliferation in the context of the occurrence of occult neck disease and distant metastases. 
SMF appearance has recently been shown to be associated with significantly lower survival 
rates in several types of carcinomas including breast and colorectal
15,16
.
 
However, there are 
only few studies in the English literature regarding the role of these cells in OSCC. Lewis et 
al
5
 studied in vitro cell lines of OSCC and observed that cancer cells through transforming 
growth factor beta (TGF-β) secretion induce myofibroblast differentiation, while 
myofibroblasts promoted cancer cell invasion into matrix gell through high hepatocyte growth 
factor (HGF) secretion. These findings imply the existence of a double paracrine mechanism 
between cancer cells and myofibroblasts. Similar results were obtained by Kellerman et al
17
.  
 
Sobral et al
18 
showed that myofibroblast clones induce increased production of 
metalloproteinases by cancer cells. Additionally, the authors demonstrated that 
myofibroblasts promote the proliferative activity of OSCC by upregulating activin A, a 
member of the TGF-β superfamily of proteins. In an experimental study on carcinogenesis 
with 4NQO in the tongue mucosa of Wistar rats, Vered et al
19 
showed that SMF were not 


associated with normal, hyperkeratotic/hyperplastic and dysplastic epithelium, irrespective of 
location along the tongue and the severity of the dysplastic changes, suggesting that increased 
number of SMF occurred simultaneously with the appearance of the carcinoma. In agreement 
with previous findings, Kellerman et al
20
, confirmed the presence of myofibroblasts only in 
the tumour stroma, especially at the invasive front of the carcinoma. This is completely 
opposite to what has been reported in other types of human carcinoma in which 
myofibroblasts were found prior to the invasive process
21-23
.
 
The findings in our study, which 
showed a statistically significant association between the frequency of myofibroblast 
appearance and poorer survival rates, are in accordance with prior reports
20,24-26
. On the other 
hand, some authors did not find a significant association between myofibroblasts and patients 
survival
17
.
 
SMF scores were statistically insignificant with respect to local recurrence (P = 
0.064). On the contrary, Vered et al
24 
observed that abundance of SMF had an independent 
adverse effect on local control.
 
In our study, lymph node metastases and regional recurrence 
occurred more frequently in the abundant myofibroblast group, which was also demonstrated 
by the findings of other authors
17,26
.
 
However, this is the first study addressing its proliferation 
regarding occurrence of occult neck disease. Furthermore, to our knowledge, this is the first 
evidence showing a significantly increased occurrence of distant metastases in patients with 
abundant myofibroblast appearance. Myofibroblast appearance increased with increasing 
tumor invasiveness, although no statistically significant correlation was found (P = 0.089). In 
a series of 84 biopsy materials from patients with OSCC, Kawashiri et al
26 
observed similar 
results, suggesting that the frequency of these cells increased gradually with mode of 
invasion. In addition, de-Assis et al
27 
found that the presence of SMF was higher in tumors 
with a more diffuse histological pattern of invasion.  
 


Recent evidence suggests that myofibroblasts represent the main effector of tumor-associated 
stroma, which facilitate the invasion process and inhibit the host immune response. Also there 
is increasing evidence that some of SMF actually represent epithelial malignant cells that 
have undergone epithelial-mesenhymal transition (EMT), the process by which tumour cells 
lose E-cadherin-dependent intercellular adhesion and enhance motility, thus becoming able to 
penetrate into surrounding tissues
28
.
 
This hypothesis was further supported by the triple 
immunostaining procedure, which showed that loss of E-cadherin among carcinoma cells 
being in direct contact with adjacent SMF
24
.
 
Furthermore, carcinoma cells can induce a 
reversal of these changes, termed mesenchymal-to-epithelial transitions (METs), by which 
carcinoma-derived stromal cells adopt epithelial characteristics establishing new tumour foci, 
which could be a reasonable explanation for the high disease reccurence and poorer survival 
rates obtained when an abundance of myofibroblasts was found
29
. 
 
In addition, some authors demonstrated that interaction of SMF with OSCC cells leads to an 
activation of the EGFR signalling system in tumor with critical role not only in increased 
proliferation and development of EMT but also in intratumor lymphangiogenesis
30
.
 
These 
results indicate possible influence of EGFR-inhibitor therapy.  
 
Finally, administration of a fibroblast inhibitor (transilat) used to treat hypertrophic scars and 
keloids in an in vivo model significantly suppresed tumor growth and cervical lymph node 
metastasis occurence in nude mice
26
.
 
This biological interaction may be clinically relevant 
targeted therapy in patients with oral squamous cell carcinoma.  
 
This study has all limitations associated with retrospective study. Another clear weakness of 
this analysis is inability to test molecular mechanisms by which myofibroblasts contribute to 


biological aggressivness of OSCCs. Although we have demonstrated that increase in 
myofibroblasts correlates with higher T stage, another possible explanation for this 
phenomenon is that myofibroblasts could just be a marker for more advanced disease and as 
such have no prognostic value beyond the clinical T size. Further investigations are needed to 
clarify whether these stromal cells can act as separate prognostic marker, or whether they 
merely reflect primary tumor size. Also, large prospective studies are necessary to clarify if 
the number of myofibroblasts in the tumor stroma (determined preoperatively in biopsy 
material) can help in decision making regarding the need for elective neck dissection or 
radiotherapy after surgical treatment. On the other hand, we believe that this data provide 
insights into important prognosticators which may be useful to define optimal treatment of 
OSCC in elective settings. 
 
In conclusion, we have demonstrated that an abundant presence of myofibroblasts leads to a 
more aggressive phenotype of the OSCCs, resulting in a significantly increased presence of 
occult metastases, regional recurrence and distant metastases as well as lower survival rates. 
The multivariate model derived from this study identified high myofibroblast score as 
independent predictor of occult neck disease thus determining the patients most likely to 
benefit from elective neck dissection. Therefore, myofibroblasts in oral cancer facilitate tumor 
growth and metastatic spread. Further investigations of stromal interactions and phenotypic 
characteristics of myofibroblasts at the invasive front are needed in order to provide new 
diagnostic markers or anti-cancer therapeutic modalities. 
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CAPTIONS TO FIGURES 
Figure 1. Less than 25% of tumor-associated stromal cells express SMA reactivity 
 
Figure 2. Approximately 50% of tumor-associated stromal cells express SMA reactivity 
 
 
 
 
 


Figure 3. Almost 100% of tumor-associated stromal cells express SMA reactivity 
 
Figure 4. Disease-specific survival of the patients with abundant myofibroblasts and patients 
with scanty myofibroblast appearance. The two curves are statistically significant different (P 
= 0.009). 
 
 

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Table 1. Clinicopathological features of 152 patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics Number of patients (%) 
Age (years) 
60 
>60 
 
85 (55.9) 
67 (44.1) 
Gender 
Male 
Female 
 
124 (81.6) 
28 (18.4) 
Primary site 
Flour of the mouth 
Tongue 
Retromolar space 
Lower gingiva 
 
72 (47.3) 
43 (28.3) 
22 (14.5) 
15 (9.9) 
T classification 
T1 
T2 
T3 
 
37 (24.3) 
98 (64.5) 
17 (11.2) 
Margin status 
Negative 
Positive 
 
142 (93.4) 
10 (6.6) 
Differentiation 
Well 
Moderate 
Poor 
 
72 (47.4) 
43 (28.3) 
37 (24.3) 
Mode of invasion 
1 
2 
3 
4 
 
10 (6.6) 
28 (18.4) 
53 (34.9) 
61 (40.1) 
Perineural invasion 
No 
Yes 
 
74 (48.7) 
78 (51.3) 
Recurrence 
Local 
Regional 
Distant 
 
20 (13.1) 
12 (7.9) 
21 (13.8) 
Survival 
Alive 
Dead 
 
118 (77.6) 
34 (22.4) 


Table 2. Correlation of the myofibroblasts appearance and  clinocopathological data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters Myofibroblasts 
low scores        high scores 
P-value 
Age 
 60 
> 60 
                
21                       64 
21                       46 
 
 
0.368 
Gender 
Male 
Female 
 
34                       90 
  8                       20 
 
 
1.00 
T stage 
T1 
T2 
T3 
 
            15                       22 
            25                       73   
  2                       15 
 
 
 
0.019 
N stage 
pN0 
pN+ 
                 
            38                       58 
   4                       52  
 
 
<0.001 
Local recurrence 
No 
Yes 
 
            40                       92      
  2                       18 
 
 
0.064 
Regional recurrence 
No 
Yes 
 
            42                       98 
  0                       12 
 
 
0.037 
Distant metastases 
No 
Yes 
 
            41                       90 
   1                       20 
 
 
0.008 
Mode of invasion 
1 
2 
3 
4 
 
              4                         6 
            11                       17                             
            13                       40 
14                       47 
 
 
 
0.089 
Bone invasion 
No 
Yes 
 
            15                       46 
  4                       19   
 
 
0.570
a 
Margin 
Negative 
Positive 
 
            39                     103 
  3                         7 
 
 
1.00 


Table 3. Univariate and multivariate analysis of variables related to regional metastases. 
Parameter 
Regional metastases 
Univariate statistics 
Multivariate 
statistics* 
No Yes 
Regression 
coefficients 
Probability Odds ratio Odds ratio 
N (%) N (%) b ± SE (b) P value OR (95% CI) OR (95% CI) 
Age  
≤ 60 
> 60 
 
51 (33.5) 
45 (29.6) 
 
 
34 (22.4) 
22 (14.5) 
 
– 
–0.31 ± 0.34 
 
 
0.364 
 
 
0.73 (0.38-1.43) 
 
 
– 
Gender 
Male 
Female 
 
78 (51.3) 
18 (11.8) 
 
46 (30.3) 
10 (6.6) 
 
– 
–0.06 ± 0.44 
 
 
0.891 
 
 
0.94 (0.4-2.21) 
 
 
– 
 
T stage 
T1 
T2 
T3 
 
 
26 (17.1) 
61 (40.1) 
  9 (5.9) 
 
11 (7.2) 
37 (24.4) 
 8 (5.3) 
 
– 
0.36 ± 0.42 
0.74 ± 0.6 
 
 
0.386 
0.219 
 
 
1.43 (0.64-3.24) 
2.1 (0.64-6.87) 
 
 
– 
 
Tumor thickness 
≤ 5mm 
> 5mm 
 
Tumor volume 
≤ 1cm3 
> 1cm
3 
 
 
 
 
 
63 (65.6)  
33 (34.4)   
 
 
 
 
 
33 (58.9) 
23 (41.1) 
 
 
 
 
0.29 ± 0.35 
 
 
 
 
0.409 
 
 
 
 
1.33 (0.67-2.62) 
 
 
Primary site 
Flour of the mouth 
Tongue 
 
45 (29.6) 
25 (16.4) 
 
27 (17.8) 
18 (11.8) 
 
– 
0.18 ± 0.39 
 
 
0.643 
 
 
1.2 (0.56-2.59) 
 
 
_ 


 
 
 
 
 
 
 
 
 
 
 
 
 
 
*
Only factors which demonstrated statistical significancy on univariate analysis were submitted to multivariate statistics 
Retromolar space 
Lower gingiva 
 
14 (9.2) 
12 (7.9) 
8 (5.3) 
3 (2.0) 
–0.05 ± 0.5 
–0.88 ± 0.69 
0.923 
0.204 
 
0.95 (0.35-2.57) 
0.42 (0.11-1.61) 
Margin status 
Negative 
Positive 
 
89 (58.5) 
  7 (4.6) 
 
 
53 (34.9) 
  3 (2.0) 
 
– 
–0.33 ± 0.71 
 
 
0.644 
 
 
0.72 (0.18-2.9) 
 
 
– 
 
Differentiation 
Well 
Moderate 
Poor 
 
 
52 (34.2) 
26 (17.1) 
18 (11.8) 
 
20 (13.2) 
17 (11.2) 
19 (12.5) 
 
– 
0.53 ± 0.41 
1 ± 0.42 
 
 
0.194 
0.017 
 
 
1.7 (0.76-3.78) 
2.74 (1.2-6.27) 
 
 
1.5 (0.64-3.54) 
2.31 (1.02-5.25) 
Perineural invasion 
No 
Yes 
 
 
53 (34.9) 
43 (28.3) 
 
21 (13.8) 
35 (23.0) 
 
– 
0.72 ± 0.34 
 
 
0.036 
 
 
2.05 (1.04-4.03) 
 
 
1.44 (0.69-2.99) 
Myofibroblasts 
low scores 
high scores  
 
Laminin 
Fibronectin 
CD 34 
 
38 (25) 
58 (38.2) 
 
4 (2.6) 
52 (34.2) 
 
 
2.14 ± 0.56 
 
 
<0.001 
 
 
8.52 (2.85-25.49) 
 
 
8.68 (2.86-26.29) 
 
 
 
